English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  DetailsSummary

Released
Journal Article

Semi-synthetic glycoconjugate vaccine lead against Acinetobacter baumannii 17978

MPS-Authors
/persons/resource/persons242817

Sianturi,  Julinton
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons251980

Priegue,  Patricia
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons121849

Seeberger,  Peter H.       
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

Article.pdf
(Publisher version), 8MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Sianturi, J., Priegue, P., Hu, J., Yin, J., & Seeberger, P. H. (2022). Semi-synthetic glycoconjugate vaccine lead against Acinetobacter baumannii 17978. Angewandte Chemie International Edition, 61(41): e202209556. doi:10.1002/anie.202209556.


Cite as: https://hdl.handle.net/21.11116/0000-000A-E296-D
Abstract
Acinetobacter baumannii is a opportunistic bacterial pathogen responsible for serious nosocomial infections that is becoming increasingly resistant against antibiotics. Capsular polysaccharides (CPS) that cover A. baumannii are a major virulence factor that play an important role in pathogenesis, are used to assign serotypes and provide the basis for vaccine development. Synthetic oligosaccharides resembling the CPS of A. baumannii 17978 were printed onto microarray slides and used to screen sera from patients infected with A. baumannii as well as a monoclonal mouse antibody (mAb C8). A synthetic oligosaccharide emerged from glycan array screening as lead for the development of a vaccine against A. baumannii 17978. Tetrasaccharide 20 is a key epitope for recognition by an antibody and is a vaccine lead.